248 related articles for article (PubMed ID: 29076131)
1. Minimal residual disease in non-Hodgkin lymphoma - current applications and future directions.
Chase ML; Armand P
Br J Haematol; 2018 Jan; 180(2):177-188. PubMed ID: 29076131
[TBL] [Abstract][Full Text] [Related]
2. Circulating Tumor DNA to Monitor Therapy for Aggressive B-Cell Lymphomas.
Kwok M; Wu SP; Mo C; Summers T; Roschewski M
Curr Treat Options Oncol; 2016 Sep; 17(9):47. PubMed ID: 27461036
[TBL] [Abstract][Full Text] [Related]
3. MRD detection in B-cell non-Hodgkin lymphomas using Ig gene rearrangements and chromosomal translocations as targets for real-time quantitative PCR.
Pott C; Brüggemann M; Ritgen M; van der Velden VH; van Dongen JJ; Kneba M
Methods Mol Biol; 2013; 971():175-200. PubMed ID: 23296964
[TBL] [Abstract][Full Text] [Related]
4. Clinical relevance of minimal residual disease monitoring in non-Hodgkin's lymphomas: a critical reappraisal of molecular strategies.
Corradini P; Ladetto M; Pileri A; Tarella C
Leukemia; 1999 Nov; 13(11):1691-5. PubMed ID: 10557040
[TBL] [Abstract][Full Text] [Related]
5. A novel non-Hodgkin lymphoma murine model closer to the standard clinical scenario.
Bascuas T; Moreno M; Mónaco A; Reyes L; Paolino A; Oliver P; Kramer MG; Engler H; Pacheco JP; Grille S; Chabalgoity JA
J Transl Med; 2016 Nov; 14(1):323. PubMed ID: 27876058
[TBL] [Abstract][Full Text] [Related]
6. Minimal Residual Disease Assessment in Lymphoma: Methods and Applications.
Herrera AF; Armand P
J Clin Oncol; 2017 Dec; 35(34):3877-3887. PubMed ID: 28933999
[TBL] [Abstract][Full Text] [Related]
7. Detection of T-cell receptor delta gene rearrangement in T-cell malignancies by clonal specific polymerase chain reaction and its application to detect minimal residual disease.
Chan DW; Liang R; Kwong YL; Chan V
Am J Hematol; 1996 Jul; 52(3):171-7. PubMed ID: 8756082
[TBL] [Abstract][Full Text] [Related]
8. Specificity of immunoglobulin high-throughput sequencing minimal residual disease monitoring in non-Hodgkin lymphomas.
Shukla ND; Schroers-Martin JG; Sworder BJ; Kathuria KR; Alig SK; Frank MJ; Miklos DB; Coutre S; Diehn M; Khodadoust MS; Roschewski M; Kurtz DM; Alizadeh AA
Blood Adv; 2024 Feb; 8(3):780-784. PubMed ID: 38147627
[No Abstract] [Full Text] [Related]
9. Dynamic monitoring of circulating tumor DNA in non-Hodgkin lymphoma.
Roschewski M; Staudt LM; Wilson WH
Blood; 2016 Jun; 127(25):3127-32. PubMed ID: 27081097
[TBL] [Abstract][Full Text] [Related]
10. Liquid biopsy in tissue-born lymphomas.
Spina V; Rossi D
Swiss Med Wkly; 2019 Jan; 149():w14709. PubMed ID: 30673117
[TBL] [Abstract][Full Text] [Related]
11. Significance of minimal residual disease in lymphoid malignancies.
Brüggemann M; Pott C; Ritgen M; Kneba M
Acta Haematol; 2004; 112(1-2):111-9. PubMed ID: 15179011
[TBL] [Abstract][Full Text] [Related]
12. Immunoglobulin High Throughput Sequencing (Ig-HTS) Minimal Residual Disease (MRD) Analysis is an Effective Surveillance Tool in Patients With Mantle Cell Lymphoma.
Rezazadeh A; Pruett J; Detzner A; Edwin N; Hamadani M; Shah NN; Fenske TS
Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):254-259. PubMed ID: 38195321
[TBL] [Abstract][Full Text] [Related]
13. Stance of MRD in Non-Hodgkin's Lymphoma and its upsurge in the novel era of cell-free DNA.
Garg S; Kumar A; Gupta R
Clin Transl Oncol; 2021 Nov; 23(11):2206-2219. PubMed ID: 33991328
[TBL] [Abstract][Full Text] [Related]
14. Molecular Monitoring of Cell-Free Circulating Tumor DNA in Non-Hodgkin Lymphoma.
Melani C; Roschewski M
Oncology (Williston Park); 2016 Aug; 30(8):731-8, 744. PubMed ID: 27539624
[TBL] [Abstract][Full Text] [Related]
15. Molecular remission and non-Hodgkin's lymphoma.
Darby AJ; Johnson PW
Best Pract Res Clin Haematol; 2002 Sep; 15(3):549-62. PubMed ID: 12468405
[TBL] [Abstract][Full Text] [Related]
16. The biological markers of non-Hodgkin's lymphomas: their role in diagnosis, prognostic assessment and therapeutic strategy.
Morra E
Int J Biol Markers; 1999; 14(3):149-53. PubMed ID: 10569136
[TBL] [Abstract][Full Text] [Related]
17. Does MRD have a role in the management of iNHL?
Giudice ID; Starza ID; Foà R
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):320-330. PubMed ID: 34889425
[TBL] [Abstract][Full Text] [Related]
18. [Minimal residual disease in follicular and mantle cell lymphoma. Detection using quantitative molecular monitoring of circulating lymphoma cells].
Schüler F; Hirt C; Dölken L; Krüger W; Dölken G
Dtsch Med Wochenschr; 2005 Sep; 130(38):2130-4. PubMed ID: 16172952
[TBL] [Abstract][Full Text] [Related]
19. Assessment of minimal residual disease in childhood non-hodgkin lymphoma by polymerase chain reaction using patient-specific primers.
Sabesan V; Cairo MS; Lones MA; Perkins SL; Morris E; Sposto R; Van De Ven C; Shiramizu B
J Pediatr Hematol Oncol; 2003 Feb; 25(2):109-13. PubMed ID: 12571460
[TBL] [Abstract][Full Text] [Related]
20. Minimal Residual Disease in Indolent Lymphomas: A Critical Assessment.
Grimaldi D; Genuardi E; Ferrante M; Ferrero S; Ladetto M
Curr Treat Options Oncol; 2018 Nov; 19(12):71. PubMed ID: 30402764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
